Hsbc Holdings PLC Invests $13.46 Million in Revolution Medicines, Inc. $RVMD

Key Points

• HSBC Holdings initiated a $13.46 million position in Revolution Medicines, purchasing 71,816 shares during the second quarter. Institutional investors collectively own 94.34% of RVMD.
• Investor sentiment has improved following the FDA approval of RASONQUE for metastatic pancreatic cancer, with several analysts raising price targets and maintaining Buy or Outperform ratings.
• Despite the positive outlook, Revolution Medicines remains unprofitable: it reported a quarterly EPS loss of $3.06, missing estimates, while recent insider stock sales and the execution risks surrounding RASONQUE’s commercial launch remain concerns.

Hsbc Holdings PLC bought a new stake in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 71,816 shares of the company's stock, valued at approximately $13,458,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Revolution Medicines by 6.7% during the 4th quarter. Vanguard Group Inc. now owns 16,719,886 shares of the company's stock worth $1,331,739,000 after buying an additional 1,056,792 shares during the last quarter. Janus Henderson Group PLC grew its holdings in shares of Revolution Medicines by 8.3% in the 4th quarter. Janus Henderson Group PLC now owns 12,303,502 shares of the company's stock valued at $980,036,000 after acquiring an additional 947,448 shares in the last quarter. Nextech Invest Ltd. increased its position in shares of Revolution Medicines by 20.7% in the fourth quarter. Nextech Invest Ltd. now owns 7,601,087 shares of the company's stock valued at $332,472,000 after acquiring an additional 1,304,347 shares during the last quarter. Paradigm Biocapital Advisors LP increased its position in shares of Revolution Medicines by 6.8% in the fourth quarter. Paradigm Biocapital Advisors LP now owns 6,644,403 shares of the company's stock valued at $529,227,000 after acquiring an additional 421,112 shares during the last quarter. Finally, Bellevue Group AG raised its holdings in Revolution Medicines by 21.7% during the third quarter. Bellevue Group AG now owns 5,573,838 shares of the company's stock worth $260,298,000 after acquiring an additional 994,538 shares in the last quarter. 94.34% of the stock is currently owned by institutional investors and hedge funds.

Key Headlines Impacting Revolution Medicines

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Landmark FDA approval: RASONQUE is described as the first broad RAS-targeted medicine approved for metastatic pancreatic cancer, addressing a disease with limited treatment options and potentially validating Revolution Medicines’ RAS/MAPK drug-development platform. FDA approval announcement
• Positive Sentiment: Commercial opportunity expands: Analysts said the RASONQUE label creates a sizable opportunity, while RBC viewed the company’s planned launch as rapid. Management’s discussion also emphasized the approval’s implications for broader RAS-driven cancer treatment and future indications. Rasonque label expansion analysis
• Positive Sentiment: Higher analyst targets: Truist raised its price target from $231 to $239 and maintained a Buy rating, while Wedbush increased its target from $201 to $225 and kept an Outperform rating. These revisions reflect improved confidence following the approval. Analyst price target changes
• Neutral Sentiment: Pricing and launch execution will matter: Revolution Medicines priced RASONQUE at approximately $39,800 per month. The price supports substantial revenue potential, but payer coverage, patient access and real-world adoption could influence how quickly the approval translates into sales. Rasonque pricing article
• Negative Sentiment: Insider selling and ongoing losses remain risks: Insider Mark Goldsmith sold 80,000 shares for roughly $16.7 million, reducing his holdings by about 23%. Revolution Medicines also remains unprofitable, and its latest quarterly loss exceeded analyst expectations, so the stock’s valuation depends heavily on successful commercialization and pipeline progress. Insider sale report

Revolution Medicines Trading Up 2.7%

Revolution Medicines stock opened at $221.15 on Friday. The stock has a 50-day simple moving average of $192.43 and a 200 day simple moving average of $148.17. The stock has a market capitalization of $47.40 billion, a P/E ratio of -25.07 and a beta of 1.39. The company has a debt-to-equity ratio of 0.40, a quick ratio of 11.38 and a current ratio of 11.38. Revolution Medicines, Inc. has a 52 week low of $37.56 and a 52 week high of $224.31.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The company reported ($3.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.04) by ($1.02). During the same quarter in the previous year, the company posted ($1.31) earnings per share. Analysts expect that Revolution Medicines, Inc. will post -8.82 earnings per share for the current year.

Analyst Upgrades and Downgrades

RVMD has been the subject of several recent research reports. Royal Bank Of Canada increased their price target on Revolution Medicines from $203.00 to $251.00 and gave the company an "outperform" rating in a research report on Thursday. Piper Sandler boosted their price target on Revolution Medicines to $172.00 and gave the stock an "overweight" rating in a research report on Thursday, May 7th. Guggenheim upped their price objective on Revolution Medicines from $235.00 to $240.00 and gave the stock a "buy" rating in a research note on Thursday, August 6th. Truist Financial increased their price objective on Revolution Medicines from $231.00 to $239.00 and gave the company a "buy" rating in a report on Thursday. Finally, HC Wainwright boosted their target price on shares of Revolution Medicines from $195.00 to $280.00 and gave the stock a "buy" rating in a report on Thursday. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $193.28.

Insider Buying and Selling at Revolution Medicines

In other Revolution Medicines news, COO Margaret A. Horn sold 60,400 shares of the firm's stock in a transaction on Monday, June 15th. The stock was sold at an average price of $160.17, for a total transaction of $9,674,268.00. Following the completion of the sale, the chief operating officer owned 158,222 shares of the company's stock, valued at $25,342,417.74. This trade represents a 27.63% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Sushil Patel sold 5,580 shares of Revolution Medicines stock in a transaction on Monday, June 29th. The stock was sold at an average price of $187.99, for a total transaction of $1,048,984.20. Following the transaction, the director directly owned 21,656 shares of the company's stock, valued at approximately $4,071,111.44. This trade represents a 20.49% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 212,497 shares of company stock worth $38,206,486 in the last three months. 7.60% of the stock is owned by insiders.

Revolution Medicines Company Profile

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company's research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.

Want to see what other hedge funds are holding RVMD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source